Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Zentalis Pharmaceuticals Inc’s stock clocked out at $1.34, down -2.90% from its previous closing price of $1.38. In other words, the price has decreased by -$2.90 from its previous closing price. On the day, 0.95 million shares were traded. ZNTL stock price reached its highest trading level at $1.385 during the session, while it also had its lowest trading level at $1.33.
Ratios:
To gain a deeper understanding of ZNTL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.76 and its Current Ratio is at 7.76. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 15 ’25 when Matrix Capital Management Comp sold 7,500,000 shares for $1.33 per share. The transaction valued at 9,975,000 led to the insider holds 6,459,973 shares of the business.
Myers Scott Dunseth bought 21,000 shares of ZNTL for $29,373 on Apr 30 ’25. The Director now owns 281,192 shares after completing the transaction at $1.40 per share. On Feb 06 ’25, another insider, Bruns Ingmar, who serves as the Chief Medical Officer of the company, bought 20,000 shares for $2.28 each. As a result, the insider paid 45,656 and bolstered with 36,629 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 96816040 and an Enterprise Value of -143423952. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.60 while its Price-to-Book (P/B) ratio in mrq is 0.38. Its current Enterprise Value per Revenue stands at -5.339 whereas that against EBITDA is 0.946.
Stock Price History:
The Beta on a monthly basis for ZNTL is 1.75, which has changed by -0.52901024 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, ZNTL has reached a high of $3.33, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is -8.02%, while the 200-Day Moving Average is calculated to be -8.63%.
Shares Statistics:
It appears that ZNTL traded 665.98K shares on average per day over the past three months and 576980 shares per day over the past ten days. A total of 72.25M shares are outstanding, with a floating share count of 59.50M. Insiders hold about 17.65% of the company’s shares, while institutions hold 65.06% stake in the company. Shares short for ZNTL as of 1764288000 were 5129111 with a Short Ratio of 7.70, compared to 1761868800 on 4990371. Therefore, it implies a Short% of Shares Outstanding of 5129111 and a Short% of Float of 8.8599995.
Earnings Estimates
A comprehensive evaluation of Zentalis Pharmaceuticals Inc (ZNTL) is underway, with the input of 7.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.38 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$1.37 and -$1.95 for the fiscal current year, implying an average EPS of -$1.76. EPS for the following year is -$1.6, with 7.0 analysts recommending between -$1.05 and -$2.27.
